Antimicrobial activity of tazobactam/piperacillin against clinical isolates from 2001 to 2006 in Japan

Keizo Yamaguchi, Yoshikazu Ishii, Yoshihisa Itoh, Mitsuo Kaku, Tatsuo Yamamoto, Yoshio Kobayashi, Shigemi Kondoh, Hisashi Baba, Satoshi Ichiyama, Kiyoharu Yamanaka, Nobuchika Kusano, Hitoshi Miyamoto, Tetsuro Matsumoto, Shigeru Kohno

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Antimicrobial susceptibility to beta-lactam antibiotics including tazobactam/piperacillin and beta-lactamases production were evaluated for 3,213 clinical isolates of 11 strains, 2 spp., and 1 group obtained from 12 hospitals from 2001 to 2006 in Japan. Susceptibility to tazobactam/piperacillin calculated based on Clinical and Laboratory Standards Institute breakpoints were 59.2%-100%. Tazobactam/piperacillin showed up to 90% susceptibility of 8 strains, 1 sp., and 1 group. Chronological MIC increase of tazobactam/ piperacillin was not seen in any species. Isolation frequency of beta-lactamases producing strains increased in Escherichia coli and Serratia marcescens from 68.1% to 97.3% and from 81.0% to 96.2%. Isolation frequency of metallo beta-lactamase(MBL) producing strains increased in Pseudomonas aeruginosa from 5.8% to 8.6%, and those of extended-spectrum beta-lactamases (ESBLs) producing strains also increased in E. coli, Klebsiella pneumoniae and Proteus mirabilis from 1.8% to 6.4%, from 1.1% to 4.7% and from 1.6% to 9.2%. Antimicrobial activity of tazobactam/piperacillin against MBL producing strains was superior to other beta-lactam antibiotics, as were those against ESBLs producing strains for other beta-lactam antibiotics other than flomoxef. Results for tazobactam/piperacillin susceptibility of clinical strains isolated in Japan from 2001 to 2006 showed that tazobactam/piperacillin maintained sufficient antibacterial activity against these strains, including beta-lactamase producing strains, although the isolation frequency of MBL and ESBLs producing strains increased.

Original languageEnglish
Pages (from-to)177-187
Number of pages11
JournalJapanese Journal of Chemotherapy
Volume59
Issue number2
Publication statusPublished - Mar 2011

Fingerprint

beta-Lactamases
Japan
beta-Lactams
Anti-Bacterial Agents
Escherichia coli
tazobactam drug combination piperacillin
Proteus mirabilis
Serratia marcescens
Klebsiella pneumoniae
Pseudomonas aeruginosa

Keywords

  • Antibacterial activity
  • Post-marketing surveillance
  • Tazobactam/piperacillin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Yamaguchi, K., Ishii, Y., Itoh, Y., Kaku, M., Yamamoto, T., Kobayashi, Y., ... Kohno, S. (2011). Antimicrobial activity of tazobactam/piperacillin against clinical isolates from 2001 to 2006 in Japan. Japanese Journal of Chemotherapy, 59(2), 177-187.

Antimicrobial activity of tazobactam/piperacillin against clinical isolates from 2001 to 2006 in Japan. / Yamaguchi, Keizo; Ishii, Yoshikazu; Itoh, Yoshihisa; Kaku, Mitsuo; Yamamoto, Tatsuo; Kobayashi, Yoshio; Kondoh, Shigemi; Baba, Hisashi; Ichiyama, Satoshi; Yamanaka, Kiyoharu; Kusano, Nobuchika; Miyamoto, Hitoshi; Matsumoto, Tetsuro; Kohno, Shigeru.

In: Japanese Journal of Chemotherapy, Vol. 59, No. 2, 03.2011, p. 177-187.

Research output: Contribution to journalArticle

Yamaguchi, K, Ishii, Y, Itoh, Y, Kaku, M, Yamamoto, T, Kobayashi, Y, Kondoh, S, Baba, H, Ichiyama, S, Yamanaka, K, Kusano, N, Miyamoto, H, Matsumoto, T & Kohno, S 2011, 'Antimicrobial activity of tazobactam/piperacillin against clinical isolates from 2001 to 2006 in Japan', Japanese Journal of Chemotherapy, vol. 59, no. 2, pp. 177-187.
Yamaguchi K, Ishii Y, Itoh Y, Kaku M, Yamamoto T, Kobayashi Y et al. Antimicrobial activity of tazobactam/piperacillin against clinical isolates from 2001 to 2006 in Japan. Japanese Journal of Chemotherapy. 2011 Mar;59(2):177-187.
Yamaguchi, Keizo ; Ishii, Yoshikazu ; Itoh, Yoshihisa ; Kaku, Mitsuo ; Yamamoto, Tatsuo ; Kobayashi, Yoshio ; Kondoh, Shigemi ; Baba, Hisashi ; Ichiyama, Satoshi ; Yamanaka, Kiyoharu ; Kusano, Nobuchika ; Miyamoto, Hitoshi ; Matsumoto, Tetsuro ; Kohno, Shigeru. / Antimicrobial activity of tazobactam/piperacillin against clinical isolates from 2001 to 2006 in Japan. In: Japanese Journal of Chemotherapy. 2011 ; Vol. 59, No. 2. pp. 177-187.
@article{3ea499c25f9342128a3b3a0e606b587c,
title = "Antimicrobial activity of tazobactam/piperacillin against clinical isolates from 2001 to 2006 in Japan",
abstract = "Antimicrobial susceptibility to beta-lactam antibiotics including tazobactam/piperacillin and beta-lactamases production were evaluated for 3,213 clinical isolates of 11 strains, 2 spp., and 1 group obtained from 12 hospitals from 2001 to 2006 in Japan. Susceptibility to tazobactam/piperacillin calculated based on Clinical and Laboratory Standards Institute breakpoints were 59.2{\%}-100{\%}. Tazobactam/piperacillin showed up to 90{\%} susceptibility of 8 strains, 1 sp., and 1 group. Chronological MIC increase of tazobactam/ piperacillin was not seen in any species. Isolation frequency of beta-lactamases producing strains increased in Escherichia coli and Serratia marcescens from 68.1{\%} to 97.3{\%} and from 81.0{\%} to 96.2{\%}. Isolation frequency of metallo beta-lactamase(MBL) producing strains increased in Pseudomonas aeruginosa from 5.8{\%} to 8.6{\%}, and those of extended-spectrum beta-lactamases (ESBLs) producing strains also increased in E. coli, Klebsiella pneumoniae and Proteus mirabilis from 1.8{\%} to 6.4{\%}, from 1.1{\%} to 4.7{\%} and from 1.6{\%} to 9.2{\%}. Antimicrobial activity of tazobactam/piperacillin against MBL producing strains was superior to other beta-lactam antibiotics, as were those against ESBLs producing strains for other beta-lactam antibiotics other than flomoxef. Results for tazobactam/piperacillin susceptibility of clinical strains isolated in Japan from 2001 to 2006 showed that tazobactam/piperacillin maintained sufficient antibacterial activity against these strains, including beta-lactamase producing strains, although the isolation frequency of MBL and ESBLs producing strains increased.",
keywords = "Antibacterial activity, Post-marketing surveillance, Tazobactam/piperacillin",
author = "Keizo Yamaguchi and Yoshikazu Ishii and Yoshihisa Itoh and Mitsuo Kaku and Tatsuo Yamamoto and Yoshio Kobayashi and Shigemi Kondoh and Hisashi Baba and Satoshi Ichiyama and Kiyoharu Yamanaka and Nobuchika Kusano and Hitoshi Miyamoto and Tetsuro Matsumoto and Shigeru Kohno",
year = "2011",
month = "3",
language = "English",
volume = "59",
pages = "177--187",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "2",

}

TY - JOUR

T1 - Antimicrobial activity of tazobactam/piperacillin against clinical isolates from 2001 to 2006 in Japan

AU - Yamaguchi, Keizo

AU - Ishii, Yoshikazu

AU - Itoh, Yoshihisa

AU - Kaku, Mitsuo

AU - Yamamoto, Tatsuo

AU - Kobayashi, Yoshio

AU - Kondoh, Shigemi

AU - Baba, Hisashi

AU - Ichiyama, Satoshi

AU - Yamanaka, Kiyoharu

AU - Kusano, Nobuchika

AU - Miyamoto, Hitoshi

AU - Matsumoto, Tetsuro

AU - Kohno, Shigeru

PY - 2011/3

Y1 - 2011/3

N2 - Antimicrobial susceptibility to beta-lactam antibiotics including tazobactam/piperacillin and beta-lactamases production were evaluated for 3,213 clinical isolates of 11 strains, 2 spp., and 1 group obtained from 12 hospitals from 2001 to 2006 in Japan. Susceptibility to tazobactam/piperacillin calculated based on Clinical and Laboratory Standards Institute breakpoints were 59.2%-100%. Tazobactam/piperacillin showed up to 90% susceptibility of 8 strains, 1 sp., and 1 group. Chronological MIC increase of tazobactam/ piperacillin was not seen in any species. Isolation frequency of beta-lactamases producing strains increased in Escherichia coli and Serratia marcescens from 68.1% to 97.3% and from 81.0% to 96.2%. Isolation frequency of metallo beta-lactamase(MBL) producing strains increased in Pseudomonas aeruginosa from 5.8% to 8.6%, and those of extended-spectrum beta-lactamases (ESBLs) producing strains also increased in E. coli, Klebsiella pneumoniae and Proteus mirabilis from 1.8% to 6.4%, from 1.1% to 4.7% and from 1.6% to 9.2%. Antimicrobial activity of tazobactam/piperacillin against MBL producing strains was superior to other beta-lactam antibiotics, as were those against ESBLs producing strains for other beta-lactam antibiotics other than flomoxef. Results for tazobactam/piperacillin susceptibility of clinical strains isolated in Japan from 2001 to 2006 showed that tazobactam/piperacillin maintained sufficient antibacterial activity against these strains, including beta-lactamase producing strains, although the isolation frequency of MBL and ESBLs producing strains increased.

AB - Antimicrobial susceptibility to beta-lactam antibiotics including tazobactam/piperacillin and beta-lactamases production were evaluated for 3,213 clinical isolates of 11 strains, 2 spp., and 1 group obtained from 12 hospitals from 2001 to 2006 in Japan. Susceptibility to tazobactam/piperacillin calculated based on Clinical and Laboratory Standards Institute breakpoints were 59.2%-100%. Tazobactam/piperacillin showed up to 90% susceptibility of 8 strains, 1 sp., and 1 group. Chronological MIC increase of tazobactam/ piperacillin was not seen in any species. Isolation frequency of beta-lactamases producing strains increased in Escherichia coli and Serratia marcescens from 68.1% to 97.3% and from 81.0% to 96.2%. Isolation frequency of metallo beta-lactamase(MBL) producing strains increased in Pseudomonas aeruginosa from 5.8% to 8.6%, and those of extended-spectrum beta-lactamases (ESBLs) producing strains also increased in E. coli, Klebsiella pneumoniae and Proteus mirabilis from 1.8% to 6.4%, from 1.1% to 4.7% and from 1.6% to 9.2%. Antimicrobial activity of tazobactam/piperacillin against MBL producing strains was superior to other beta-lactam antibiotics, as were those against ESBLs producing strains for other beta-lactam antibiotics other than flomoxef. Results for tazobactam/piperacillin susceptibility of clinical strains isolated in Japan from 2001 to 2006 showed that tazobactam/piperacillin maintained sufficient antibacterial activity against these strains, including beta-lactamase producing strains, although the isolation frequency of MBL and ESBLs producing strains increased.

KW - Antibacterial activity

KW - Post-marketing surveillance

KW - Tazobactam/piperacillin

UR - http://www.scopus.com/inward/record.url?scp=79953866462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953866462&partnerID=8YFLogxK

M3 - Article

VL - 59

SP - 177

EP - 187

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - 2

ER -